Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp OCF Margin

The Operating Cash Flow Margin of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Nov 11, 2026 is 21.56 %. In the previous year, Operating Cash Flow Margin was 17.99 % — a change of 19.84% (higher).

OCF Margin

21.56 %

YoY

19.84%

Last updated:

Operating Cash Flow Margin of Vcanbio Cell & Gene Engineering Corp is 2025 21.56 % . Operating Cash Flow Margin of Vcanbio Cell & Gene Engineering Corp was 2024 17.99 % . It decreases by 19.84% higher compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
9.85 CNY
Jan 1, 2019
17.41 CNY
Jan 1, 2020
18.53 CNY
Jan 1, 2021
20.90 CNY
Jan 1, 2022
16.84 CNY
Jan 1, 2023
18.81 CNY
Jan 1, 2024
17.99 CNY
Jan 1, 2025
21.56 CNY
The Vcanbio Cell & Gene Engineering Corp OCF Margin history
YEAROCF MarginYoY
21.56 %+19.84%
17.99 %-4.37%
18.81 %+11.67%
16.84 %-19.43%
20.90 %+12.83%
18.53 %+6.39%
17.41 %+76.77%
9.85 %+85.17%
5.32 %-68.97%
17.15 %+1,387.05%
1.15 %-97.52%
46.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp., Ltd. generates revenue through the development and sale of life sciences technology products. The company produces cytokines culture solutions, cosmetics, and detection reagents for domestic markets. Its business segments include cell culture, gene detection and storage, and the production of specialized biological products. The firm's domestic customers primarily purchase these products for research and commercial applications in the life sciences sector. Vcanbio focuses on cell culture and gene detection services, which are integral to its product offerings. The company's cytokines culture solutions are sold to domestic clients in the biotechnology and pharmaceutical industries. Detection reagents are also marketed to domestic laboratories and healthcare providers for diagnostic purposes. The firm leverages its 2,332 full-time employees to support research, development, and production activities. The company's product portfolio includes cosmetics alongside scientific reagents, targeting both consumer and professional markets. Domestic markets remain the primary focus for all sales, with no mention of international operations. Vcanbio's revenue streams are derived from the sale of its core products, which are developed and manufactured in-house. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

Operating Cash Flow Margin of Vcanbio Cell & Gene Engineering Corp is 21.56 % in 2025.

Operating Cash Flow Margin of Vcanbio Cell & Gene Engineering Corp changed from 17.99 % to 21.56 %, representing a 19.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Vcanbio Cell & Gene Engineering Corp with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Vcanbio Cell & Gene Engineering Corp

All Key Metrics — Vcanbio Cell & Gene Engineering Corp